Strategies to achieve systemic delivery of therapeutic cells and microbes to tumors

Bibliography

• JONES AL, SELBY P: Tumour necrosis factor: clinical relevance. Cancer Surv. (1989) 8(4):817-836.
   PubMedGoogle Scholar
• TARHINI AA, AGARWALA SS: Interleukin-2 for the treatment of melanoma. Curr. Opin. Investig Drugs (2005) 6(12):1234-1239.
   Google Scholar
• PORTA C: Maintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancer. Expert Rev. Anticancer Ther. (2006) 6(1):141-152.
   PubMed Web of Science ®Google Scholar
• CHANG AE, ROSENBERG SA: Overview of interleukin-2 as an immunotherapeutic agent. Semin. Surg. Oncol. (1989) 5(6):385-390.
   PubMed Web of Science ®Google Scholar
• BOOY EP, JOHAR D, MADDIKA S et al.: Monoclonal and bispecific antibodies as novel therapeutics. Arch. Immunol. Ther. Exp. (Warszaw) (2006) 54(2):85-101.
   PubMed Web of Science ®Google Scholar
• PARKER RC, PLUMMER HC, SIEBENMANN CO, CHAPMAN MG: Effect of Histolyticus infection and toxin on transplantable mouse tumors. Proc. Soc. Exp. Biol. Med. (1947) 66:461-467.
   PubMed Web of Science ®Google Scholar
• MALMGREN RA, FLANIGAN CC: Localization of the vegetative form of Clostridium tetani in mouse tumors following intravenous spore administration. Cancer Res. (1955) 15(7):473-478.
   PubMed Web of Science ®Google Scholar
• ZYGIERT Z: Hodgkin’s disease: remissions after measles. Lancet (1971) 1(7699):593.
   PubMed Web of Science ®Google Scholar
• HANSEN RM, LIBNOCH JA: Remission of chronic lymphocytic leukemia after smallpox vaccination. Arch. Intern. Med. (1978) 138(7):1137-1138.
   PubMed Web of Science ®Google Scholar
• KREIDER JW, BARTLETT GL, BUTKIEWICZ BL: Relationship of tumor leucocytic infiltration to host defense mechanisms and prognosis. Cancer Metastasis Rev. (1984) 3(1):53-74.
   PubMed Web of Science ®Google Scholar
• WANG E, PANELLI MC, MONSURRO V, MARINCOLA FM: A global approach to tumor immunology. Cell. Mol. Immunol. (2004) 1(4):256-265.
   Google Scholar
• BURKERT J, WRIGHT NA, ALISON MR: Stem cells and cancer: an intimate relationship. J. Pathol. (2006) 209(3):287-297.
   PubMed Web of Science ®Google Scholar
• RIBATTI D, NICO B, CRIVELLATO E, VACCA A: Endothelial progenitor cells in health and disease. Histol. Histopathol. (2005) 20(4):1351-1358.
   PubMed Web of Science ®Google Scholar
• COBALEDA C, GUTIERREZ-CIANCA N, PEREZ-LOSADA J et al.: A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia. Blood (2000) 95(3):1007-1013.
   PubMed Web of Science ®Google Scholar
• DE PALMA M, VENNERI MA, ROCA C, NALDINI L: Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat. Med. (2003) 9(6):789-795.
   Web of Science ®Google Scholar
• ROTH JA: Adenovirus p53 gene therapy. Expert Opin. Biol. Ther. (2006) 6(1):55-61.
   PubMed Web of Science ®Google Scholar
• VERREAULT M, WEBB MS, RAMSAY EC, BALLY MB: Gene silencing in the development of personalized cancer treatment: the targets, the agents and the delivery systems. Curr. Gene Ther. (2006) 6(4):505-533.
   Web of Science ®Google Scholar
• KAPLAN JM: Adenovirus-based cancer gene therapy. Curr. Gene Ther. (2005) 5(6):595-605.
   Google Scholar
• NICULESCU-DUVAZ I, SPRINGER CJ: Introduction to the background, principles, and state of the art in suicide gene therapy. Mol. Biotechnol. (2005) 30(1):71-88.
   PubMed Web of Science ®Google Scholar
• LI CY, HUANG Q, KUNG HF: Cytokine and immuno-gene therapy for solid tumors. Cell. Mol. Immunol. (2005) 2(2):81-91.
   PubMed Web of Science ®Google Scholar
• LIU Y, DEISSEROTH A: Tumor vascular targeting therapy with viral vectors. Blood (2006) 107(8):3027-3033.
   PubMed Web of Science ®Google Scholar
• HERMISTON TW, KUHN I: Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes. Cancer Gene Ther. (2002) 9(12):1022-1035.
   PubMed Web of Science ®Google Scholar
• THORNE SH, HERMISTON T, KIRN D: Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects. Semin. Oncol. (2005) 32(6):537-548.
   PubMed Web of Science ®Google Scholar
• PARATO KA, SENGER D, FORSYTH PA, BELL JC: Recent progress in the battle between oncolytic viruses and tumours. Nat. Rev. Cancer (2005) 5(12):965-976.
   PubMed Web of Science ®Google Scholar
• STRONG JE, COFFEY MC, TANG D, SABININ P, LEE PW: The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J. (1998) 17(12):3351-3362.
   PubMed Web of Science ®Google Scholar
• STOJDL DF, LICHTY B, KNOWLES S et al.: Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. (2000) 6(7):821-825.
   PubMed Web of Science ®Google Scholar
• WANG F, MA Y, BARRETT JW et al.: Disruption of Erk-dependent Type I interferon induction breaks the myxoma virus species barrier. Nat. Immunol. (2004) 5(12):1266-1274.
   PubMed Web of Science ®Google Scholar
• REICHARD KW, LORENCE RM, CASCINO CJ et al.: Newcastle disease virus selectively kills human tumor cells. J. Surg. Res. (1992) 52(5):448-453.
   PubMed Web of Science ®Google Scholar
• HEISE C, SAMPSON JA, WILLIAMS A et al.: ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents [see comments]. Nat. Med. (1997) 3(6):639-645.
   PubMed Web of Science ®Google Scholar
• HEISE C, HERMISTON T, JOHNSON L et al.: An adenovirus E1A mutant that demonstrates potent and selective antitumoral efficacy. Nat. Med. (2000) 6(10):1134-1139.
   PubMed Web of Science ®Google Scholar
• MCCART JA, HU YK, ALEXANDER HR et al.: A combined thymidine kinase/vaccinia growth factor deleted vaccinia virus as a vector for cancer gene therapy. Am. Soc. Gene Ther. (1999) 2:160.
   Google Scholar
• MINETA T, RABKIN SD, YAZAKI T, HUNTER WD, MARTUZA RL: Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med. (1995) 1(9):938-943.
   PubMed Web of Science ®Google Scholar
• GUO ZS, NAIK A, O’MALLEY ME et al.: The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res. (2005) 65(21):9991-9998.
   PubMed Web of Science ®Google Scholar
• LI Y, YU DC, CHEN Y et al.: A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res. (2001) 61(17):6428-6436.
   PubMed Web of Science ®Google Scholar
• CHEN Y, DEWEESE T, DILLEY J et al.: CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res. (2001) 61(14):5453-5460.
   PubMed Web of Science ®Google Scholar
• MULLEN JT, TANABE KK: Viral oncolysis. Oncologist (2002) 7(2):106-119.
   PubMed Web of Science ®Google Scholar
• KURIHARA T, BROUGH DE, KOVESDI I, KUFE DW: Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J. Clin. Invest. (2000) 106(6):763-771.
   PubMed Web of Science ®Google Scholar
• JOHNSON L, SHEN A, BOYLE L et al.: Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell (2002) 1(4):325-337.
   PubMed Web of Science ®Google Scholar
• POST DE, VAN MEIR EG: A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene (2003) 22(14):2065-2072.
   PubMed Web of Science ®Google Scholar
• REID T, GALANIS E, ABBRUZZESE J et al.: Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): Phase II viral, immunologic, and clinical endpoints. Cancer Res. (2002) 62(21):6070-6079.
   PubMed Web of Science ®Google Scholar
• KIRN D, HERMISTON T, MCCORMICK F: ONYX-015: Clinical data are encouraging. Nat. Med. (1998) 4(12):1341-1342.
   PubMed Web of Science ®Google Scholar
• AGHI M, MARTUZA RL: Oncolytic viral therapies – the clinical experience. Oncogene (2005) 24(52):7802-7816.
   PubMed Web of Science ®Google Scholar
• STOECKEL J, HAY JG: Drug evaluation: Reolysin-wild-type reovirus as a cancer therapeutic. Curr. Opin. Mol. Ther. (2006) 8(3):249-260.
   PubMed Web of Science ®Google Scholar
• NEMUNAITIS J, CUNNINGHAM C, BUCHANAN A et al.: Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther. (2001) 8(10):746-759.
   PubMed Web of Science ®Google Scholar
• NEMUNAITIS J, CUNNINGHAM C, RANDLEV B, KIRN D: A Phase I dose escalation trial of intravenous infusion with a replication-selective adenovirus, dl 1520, in patients with refractory cancer. Proc. Am. Soc. Clin. Oncol. (2000) 19:724 (Abstract).
   Google Scholar
• THORNE SH, TAM BY, KIRN DH, CONTAG CH, KUO CJ: Selective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacy. Mol. Ther. (2006) 13(5):938-946.
   PubMed Web of Science ®Google Scholar
• AKIYAMA M, THORNE S, KIRN D et al.: Ablating CAR and integrin binding in adenovirus vectors reduces nontarget organ transduction and permits sustained bloodstream persistence following intraperitoneal administration. Mol. Ther. (2004) 9(2):218-230.
   PubMed Web of Science ®Google Scholar
• DMITRIEV I, KRASNYKH V, MILLER CR et al.: An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J. Virol. (1998) 72(12):9706-9713.
   PubMed Web of Science ®Google Scholar
• LAQUERRE S, ANDERSON DB, STOLZ DB, GLORIOSO JC: Recombinant herpes simplex virus Type 1 engineered for targeted binding to erythropoietin receptor-bearing cells. J. Virol. (1998) 72(12):9683-9697.
   PubMed Web of Science ®Google Scholar
• KAWAKAMI Y, LI H, LAM JT et al.: Substitution of the adenovirus serotype 5 knob with a serotype 3 knob enhances multiple steps in virus replication. Cancer Res. (2003) 63(6):1262-1269.
   PubMed Web of Science ®Google Scholar
• MORIZONO K, BRISTOL G, XIE YM, KUNG SK, CHEN IS: Antibody-directed targeting of retroviral vectors via cell surface antigens. J. Virol. (2001) 75(17):8016-8020.
   PubMed Web of Science ®Google Scholar
• DOUGLAS JT, ROGERS BE, ROSENFELD ME et al.: Targeted gene delivery by tropism-modified adenoviral vectors. Nat. Biotechnol. (1996) 14(11):1574-1578.
   Google Scholar
• NAKAMURA T, PENG KW, VONGPUNSAWAD S et al.: Antibody-targeted cell fusion. Nat. Biotechnol. (2004) 22(3):331-336.
   Google Scholar
• NAKAMURA T, PENG KW, HARVEY M et al.: Rescue and propagation of fully retargeted oncolytic measles viruses. Nat. Biotechnol. (2005) 23(2):209-214.
   Google Scholar
• ZEH HJ, BARTLETT DL: Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers. Cancer Gene Ther. (2002) 9(12):1001-1012.
   PubMed Web of Science ®Google Scholar
• GALMICHE MC, RINDISBACHER L, WELS W, WITTEK R, BUCHEGGER F: Expression of a functional single chain antibody on the surface of extracellular enveloped vaccinia virus as a step towards selective tumour cell targeting. J. Gen. Virol. (1997) 78(Pt 11):3019-3027.
   PubMed Web of Science ®Google Scholar
• SHENK ET: Adenoviridae: the viruses and their replication. In: Field’s Virology. Fields BN, Knipe DM, Howley PM et al. (Eds), Lippincott-Raven, Philadelphia, PA, USA (2001):2111-2148.
   Google Scholar
• MOSS B: Poxviridae: the viruses and their replication. In: Field’s Virology. Fields BN, Knipe DM, Howley PM et al. (Eds), Lippincott-Raven, Philadelphia, PA, USA (2001):2637-2671.
   Google Scholar
• RAPER SE, CHIRMULE N, LEE FS et al.: Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. (2003) 80(1-2):148-158.
   PubMed Web of Science ®Google Scholar
• EXCOFFON KJ, HRUSKA-HAGEMAN A, KLOTZ M, TRAVER GL, ZABNER J: A role for the PDZ-binding domain of the coxsackie B virus and adenovirus receptor (CAR) in cell adhesion and growth. J. Cell Sci. (2004) 117(Pt 19):4401-4409.
   PubMed Web of Science ®Google Scholar
• OH P, LI Y, YU J et al.: Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature (2004) 429(6992):629-635.
   PubMed Web of Science ®Google Scholar
• BENENCIA F, COURREGES MC, CONEJO-GARCIA JR et al.: Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma. Hum. Gene Ther. (2005) 16(6):765-778.
   PubMed Web of Science ®Google Scholar
• WORGALL S, LEOPOLD PL, WOLFF G et al.: Role of alveolar macrophages in rapid elimination of adenovirus vectors administered to the epithelial surface of the respiratory tract. Hum. Gene Ther. (1997) 8(14):1675-1684.
   PubMed Web of Science ®Google Scholar
• WOLFF G, WORGALL S, VAN ROOIJEN N et al.: Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ. J. Virol. (1997) 71(1):624-629.
   PubMed Web of Science ®Google Scholar
• SHAYAKHMETOV DM, GAGGAR A, NI S, LI ZY, LIEBER A: Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J. Virol. (2005) 79(12):7478-7491.
   PubMed Web of Science ®Google Scholar
• PEISER L, MUKHOPADHYAY S, GORDON S: Scavenger receptors in innate immunity. Curr. Opin. Immunol. (2002) 14(1):123-128.
   PubMed Web of Science ®Google Scholar
• MATSUMURA Y, MAEDA H: A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. (1986) 46(12 Pt 1):6387-6392.
   PubMed Web of Science ®Google Scholar
• BULLER RM, PALUMBO GJ: Poxvirus pathogenesis. Microbiol. Rev. (1991) 55(1):80-122.
   PubMedGoogle Scholar
• KIM JH, OH JY, PARK BH et al.: Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol. Ther. (2006) 14(3):361-370.
   Google Scholar
• THORNE SH, HWANG TH, KIRN DH: Vaccinia virus and oncolytic virotherapy of cancer. Curr. Opin. Mol. Ther. (2005) 7(4):359-365.
   PubMed Web of Science ®Google Scholar
• FISHER KD, STALLWOOD Y, GREEN NK et al.: Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther. (2001) 8(5):341-348.
   PubMed Web of Science ®Google Scholar
• DOAN T, MASSAROTTI E: Rituximab. Drugs Today (Barc.) (2005) 41(12):785-797.
   PubMed Web of Science ®Google Scholar
• COWDEN J, PARKER SK: Intravenous immunoglobulin: production, uses and side effects. Pediatr. Infect. Dis. J. (2006) 25(7):641-642.
   PubMed Web of Science ®Google Scholar
• SCHIEDNER G, HERTEL S, JOHNSTON M et al.: Selective depletion or blockade of Kupffer cells leads to enhanced and prolonged hepatic transgene expression using high-capacity adenoviral vectors. Mol. Ther. (2003) 7(1):35-43.
   PubMed Web of Science ®Google Scholar
• TODO T, RABKIN SD, SUNDARESAN P et al.: Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum. Gene Ther. (1999) 10(17):2741-2755.
   PubMed Web of Science ®Google Scholar
• WONG RJ, PATEL SG, KIM S et al.: Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Hum. Gene Ther. (2001) 12(3):253-265.
   PubMed Web of Science ®Google Scholar
• ARLEN PM, KAUFMAN HL, DIPAOLA RS: Pox viral vaccine approaches. Semin. Oncol. (2005) 32(6):549-555.
   PubMed Web of Science ®Google Scholar
• MOROZIEWICZ D, KAUFMAN HL: Gene therapy with poxvirus vectors. Curr. Opin. Mol. Ther. (2005) 7(4):317-325.
   PubMed Web of Science ®Google Scholar
• BONNEFOY JY: Cancer vaccines. Expert Opin. Ther. Targets (2004) 8(6):521-525.
   PubMed Web of Science ®Google Scholar
• LATTIME EC, LEE SS, EISENLOHR LC, MASTRANGELO MJ: In situ cytokine gene transfection using vaccinia virus vectors. Semin. Oncol. (1996) 23(1):88-100.
   PubMed Web of Science ®Google Scholar
• MASTRANGELO MJ, MAGUIRE HC, LATTIME EC: Intralesional vaccinia/GM-CSF recombinant virus in the treatment of metastatic melanoma. Adv. Exp. Med. Biol. (2000) 465:391-400.
   PubMed Web of Science ®Google Scholar
• LATTIME EC, EISENLOHR LC, GOMELLA L, MASTRANGELO MJ: In situ immune modulation using recombinant vaccinia vectors: preclinical studies to clinical implementation. In: Gene Therapy of Cancer. Lattime EC, Gerson SL (Eds), Academic Press, San Diego, CA, USA (2002).
   Google Scholar
• BASSI P: BCG (Bacillus of Calmette Guerin) therapy of high-risk superficial bladder cancer. Surg. Oncol. (2002) 11(1-2):77-83.
   PubMed Web of Science ®Google Scholar
• ZHAO M, YANG M, MA H et al.: Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. Cancer Res. (2006) 66(15):7647-7652.
   PubMed Web of Science ®Google Scholar
• ZHAO M, YANG M, LI XM et al.: Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc. Natl. Acad. Sci. USA (2005) 102(3):755-760.
   Google Scholar
• LOW KB, ITTENSOHN M, LE T et al.: Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo. Nat. Biotechnol. (1999) 17(1):37-41.
   PubMed Web of Science ®Google Scholar
• CLAIRMONT C, LEE KC, PIKE J et al.: Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium. J. Infect. Dis. (2000) 181(6):1996-2002.
   PubMed Web of Science ®Google Scholar
• KING I, BERMUDES D, LIN S et al.: Tumor-targeted Salmonella expressing cytosine deaminase as an anticancer agent. Hum. Gene Ther. (2002) 13(10):1225-1233.
   PubMed Web of Science ®Google Scholar
• YAZAWA K, FUJIMORI M, AMANO J, KANO Y, TANIGUCHI S: Bifidobacterium longum as a delivery system for cancer gene therapy: selective localization and growth in hypoxic tumors. Cancer Gene Ther. (2000) 7(2):269-274.
   PubMed Web of Science ®Google Scholar
• LIU SC, MINTON NP, GIACCIA AJ, BROWN JM: Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Ther. (2002) 9(4):291-296.
   PubMed Web of Science ®Google Scholar
• LEMMON MJ, VAN ZIJL P, FOX ME et al.: Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Ther. (1997) 4(8):791-796.
   PubMed Web of Science ®Google Scholar
• DANG LH, BETTEGOWDA C, HUSO DL, KINZLER KW, VOGELSTEIN B: Combination bacteriolytic therapy for the treatment of experimental tumors. Proc. Natl. Acad. Sci. USA (2001) 98(26):15155-15160.
   Google Scholar
• CRITCHLEY-THORNE RJ, STAGG AJ, VASSAUX G: Recombinant Escherichia coli expressing invasin targets the Peyer’s patches: the basis for a bacterial formulation for oral vaccination. Mol. Ther. (2006) 14(2):183-191.
   PubMed Web of Science ®Google Scholar
• YANNELLI JR, WROBLEWSKI JM: On the road to a tumor cell vaccine: 20 years of cellular immunotherapy. Vaccine (2004) 23(1):97-113.
   PubMed Web of Science ®Google Scholar
• MELDER RJ, WHITESIDE TL, VUJANOVIC NL, HISERODT JC, HERBERMAN RB: A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells. Cancer Res. (1988) 48(12):3461-3469.
   PubMed Web of Science ®Google Scholar
• SASAKI A, MELDER RJ, WHITESIDE TL, HERBERMAN RB, JAIN RK: Preferential localization of human adherent lymphokine-activated killer cells in tumor microcirculation. J. Natl Cancer Inst. (1991) 83(6):433-437.
   PubMed Web of Science ®Google Scholar
• POCKAJ BA, SHERRY RM, WEI JP et al.: Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer (1994) 73(6):1731-1737.
   PubMed Web of Science ®Google Scholar
• MOINGEON P: Cancer vaccines. Vaccine (2001) 19(11-12):1305-1326.
   PubMed Web of Science ®Google Scholar
• ZOU W: Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer (2005) 5(4):263-274.
   Google Scholar
• SCHEFFOLD C, KORNACKER M, SCHEFFOLD YC, CONTAG CH, NEGRIN RS: Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab’)(2)HER2xCD3. Cancer Res. (2002) 62(20):5785-5791.
   PubMed Web of Science ®Google Scholar
• LEEMHUIS T, WELLS S, SCHEFFOLD C, EDINGER M, NEGRIN RS: A Phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol. Blood Marrow Transplant. (2005) 11(3):181-187.
   Google Scholar
• CHAN JK, HAMILTON CA, CHEUNG MK et al.: Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study. Clin. Cancer Res. (2006) 12(6):1859-1867.
   PubMed Web of Science ®Google Scholar
• LUSTER AD, ALON R, VON ANDRIAN UH: Immune cell migration in inflammation: present and future therapeutic targets. Nat. Immunol. (2005) 6(12):1182-1190.
   Google Scholar
• BORDIGNON C, RONCAROLO MG: Therapeutic applications for hematopoietic stem cell gene transfer. Nat. Immunol. (2002) 3(4):318-321.
   Google Scholar
• HAMADA H, KOBUNE M, NAKAMURA K et al.: Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy. Cancer Sci. (2005) 96(3):149-156.
   PubMed Web of Science ®Google Scholar
• LI S, TOKUYAMA T, YAMAMOTO J et al.: Bystander effect-mediated gene therapy of gliomas using genetically engineered neural stem cells. Cancer Gene Ther. (2005) 12(7):600-607.
   PubMed Web of Science ®Google Scholar
• OZAWA CR, SPRINGER ML, BLAU HM: A novel means of drug delivery: myoblast-mediated gene therapy and regulatable retroviral vectors. Annu. Rev. Pharmacol. Toxicol. (2000) 40:295-317.
   Google Scholar
• COLE C, QIAO J, KOTTKE T et al.: Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells. Nat. Med. (2005) 11(10):1073-1081.
   PubMed Web of Science ®Google Scholar
• THORNE SH, NEGRIN RS, CONTAG CH: Synergistic antitumor effects of immune cell-viral biotherapy. Science (2006) 311(5768):1780-1784.
   PubMed Web of Science ®Google Scholar
• KOMAROVA S, KAWAKAMI Y, STOFF-KHALILI MA, CURIEL DT, PEREBOEVA L: Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol. Cancer Ther. (2006) 5(3):755-766.
   Google Scholar
• THORNE SH, CONTAG CH: Using in vivo bioluminescence imaging to shed light on cancer biology. Proc. IEEE (2005) 93(4):750-762.
   Web of Science ®Google Scholar